Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGIC-I: YYB-103 in Malignant Glioma
NCT05540873Phase 1Unknown
- Sponsor
- CellabMED
- Start
- Jul 2022
- Primary completion
- Feb 2024
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IL13Ra2-specific CAR T cells in malignant glioma, sponsored by CellabMED. Primary endpoints: Dose Limiting Toxicity at 28 days, Maximum Tolerance Dose at 28 days and 1 more. Status: unknown.
02
Drugs
IL13Ra2-specific CAR T cells
03
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT05540873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05540873.